dc.contributor.author | Feyerabend, Susan | |
dc.contributor.author | Roubaud, Guilhem | |
dc.contributor.author | Oezgueroglu, Mustafa | |
dc.contributor.author | Penel, Nicolas | |
dc.contributor.author | Matsubara, Nobuaki | |
dc.contributor.author | Mehra, Niven | |
dc.contributor.author | Kolinsky, Michael P. | |
dc.contributor.author | Procopio, Giuseppe | |
dc.contributor.author | Joung, Jae Young | |
dc.contributor.author | Gravis, Gwenaelle | |
dc.contributor.author | Nishimura, Kazuo | |
dc.contributor.author | Gedye, Craig | |
dc.contributor.author | Padua, Charles | |
dc.contributor.author | Shore, Neal | |
dc.contributor.author | Thiery-Vuillemin, Antoine | |
dc.contributor.author | Saad, Fred | |
dc.contributor.author | van Alphen, Robbert | |
dc.contributor.author | Carducci, Michael A. | |
dc.contributor.author | Desai, Chintu | |
dc.contributor.author | Brickel, Neil | |
dc.contributor.author | Poehlein, Christian | |
dc.contributor.author | Del Rosario, Paula | |
dc.contributor.author | Fizazi, Karim | |
dc.date.accessioned | 2022-07-04T15:45:13Z | |
dc.date.available | 2022-07-04T15:45:13Z | |
dc.identifier.citation | Roubaud G., Oezgueroglu M., Penel N., Matsubara N., Mehra N., Kolinsky M. P. , Procopio G., Feyerabend S., Joung J. Y. , Gravis G., et al., "Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study", EUROPEAN JOURNAL OF CANCER, cilt.170, ss.73-84, 2022 | |
dc.identifier.issn | 0959-8049 | |
dc.identifier.other | av_c0b6b3db-73be-4358-9868-6316c5647bc1 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/184524 | |
dc.identifier.uri | https://doi.org/10.1016/j.ejca.2022.04.016 | |
dc.description.abstract | Background: Based on PROfound, olaparib is approved for patients with metastatic castration-resistant prostate cancer following disease progression on at least enzalutamide or abiraterone and who carry relevant alterations in DNA repair genes. To facilitate continued olaparib treatment as long as the patient derives benefit, we describe further safety assessments from PROfound focusing on the four most common adverse events (AEs) and events of special interest. | |
dc.language.iso | eng | |
dc.subject | İç Hastalıkları | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Onkoloji | |
dc.subject | Oncology | |
dc.subject | Health Sciences | |
dc.title | Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study | |
dc.type | Makale | |
dc.relation.journal | EUROPEAN JOURNAL OF CANCER | |
dc.contributor.department | Inst Bergonie , , | |
dc.identifier.volume | 170 | |
dc.identifier.startpage | 73 | |
dc.identifier.endpage | 84 | |
dc.contributor.firstauthorID | 3433990 | |